Extension Study of RA101495 for Patients With PNH Who Have Completed a RA101495 Clinical Study



Status:Recruiting
Conditions:Hematology, Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:18 - Any
Updated:2/24/2018
Start Date:July 17, 2017
End Date:January 2020
Contact:Sponsor Ra Pharmaceuticals, Inc.
Email:trials@rapharma.com
Phone:+1 617 401 4060

Use our guide to learn which trials are right for you!

A Multicenter, Open-label, Uncontrolled, Extension Study of RA101495 in Subjects With Paroxysmal Nocturnal Hemoglobinuria Who Have Completed a RA101495 Clinical Study

The purpose of this study is to enable continued access to RA101495 for patients with
paroxysmal nocturnal hemoglobinuria (PNH) after they complete a RA101495 clinical study.


Inclusion Criteria:

- Completion of a qualifying Ra Pharmaceuticals sponsored RA101495 PNH study

- Evidence of ongoing clinical benefit in the opinion of the Investigator

Exclusion criteria:

- History of meningococcal disease

- Current systemic infection or suspicion of active bacterial infection
We found this trial at
6
sites
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Duarte, CA
Click here to add this to my saved trials
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
Gosford,
Click here to add this to my saved trials
?
mi
from
Manhasset, NY
Click here to add this to my saved trials